StockGuide AI
Suivre des actions
EN RU ES DE IT PT FR
Teva Pharmaceutical Industries

Teva Pharmaceutical Industries

Prix: 34.63

Entreprise et modèle économique

Teva Pharmaceutical Industries is a global leader in generic and specialty pharmaceuticals. The company develops, manufactures, and markets a wide range of medications, including generic drugs, active pharmaceutical ingredients, and specialty treatments for various conditions. Major business segments include generics, specialty medicines, and over-the-counter products. The primary revenue sources are sales from generic pharmaceuticals and specialty treatments, with a focus on therapeutic areas such as central nervous system disorders, pain management, and respiratory diseases.

Profil d’investissement

Teva's investment profile is characterized by a focus on stability rather than aggressive growth. The company has faced challenges in revenue and earnings, making it more suitable for value investors seeking potential recovery rather than high growth. The stock may appeal to those looking for a balanced approach, given its established market presence and ongoing efforts to stabilize operations.

Site officiel

Métriques fondamentales (expérimental)

BPA (TTM) — bénéfice par action des 12 derniers mois, $
1.37 OK
Chiffre d’affaires QoQ — croissance trimestrielle du chiffre d’affaires
-15.5% ↓
Surprise BPA
6.0% meilleur que prévu
Volatilité 20 j
2.3% stable
Données FMP / FinFeed mises à jour: 2026-06-13
Reco: Conserver Potentiel: 53 Risque: 70 Mis à jour: 2026-06-13 02:47
Comment fonctionne la recommandation
Pourquoi l’IA pense cela:
Weak revenue growth raises concerns despite positive EPS surprise.

Suivre dans le portefeuille

Graphique des prix

Recommandation IA Prévision d’analyste Événement calendrier Signal positif Signal négatif Neutre / mise à jour Conserver / informatif B My buy S My sell
Changements de recommandation IA
Date Avant Après Raison
2026-06-13 02:47 Vendre Conserver Weak revenue growth raises concerns despite positive EPS surprise.
2026-06-03 02:53 Conserver Vendre Weak fundamentals and negative momentum raise significant concerns.
2026-05-08 15:26 — Conserver Mixed performance; fundamentals show weakness and uncertainty.
Prévisions des analystes
Date Analyste Action Objectif Prix alors
2026-05-06 09:48 Barclays Objectif relevé 38 → 40 35.86
2026-04-30 11:19 Piper Sandler Objectif relevé 41 → 42 35.38
2026-04-30 10:55 UBS Objectif relevé 36 → 42 35.38

Rien pour le moment